# Citius Pharmaceuticals

Source: https://onco.cc/companies/citius-pharmaceuticals/  
OnCo record `citius-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Citius Pharmaceuticals brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary.

## Summary

Citius Pharmaceuticals, based in Cranford, New Jersey, and listed as CTXR, brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary. It licensed the reformulated denileukin diftitox, known as E7777, from Eisai in 2021 and secured FDA approval in August 2024 for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one systemic therapy. OnCo links it to the denileukin diftitox drug record. Whether a revived fusion toxin finds a stable place among the newer options for a rare lymphoma is the open question. Denileukin diftitox has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cranford, New Jersey
- Type: biotech
- Website: https://www.citiuspharma.com
- Ticker: CTXR

## Sources

- Official website: https://www.citiuspharma.com

## Connected records

- drugs: [Denileukin diftitox](https://onco.cc/drugs/denileukin-diftitox/)
- companies: [Eisai](https://onco.cc/companies/eisai/)

---
JSON: https://onco.cc/api/v1/entities/citius-pharmaceuticals.json